AVEO has built a pipeline of proprietary inducible in vivo cancer models for Target Discovery and Human Response Prediction. These tissue-specific models are engineered to contain genetic mutations present in human disease.
Our Platform >

05/15/2008
   AVEO Pharmaceuticals to Present at the 2008 Citi Investment Research Global Health Care Conference
   Read More >

05/02/2008
   AVEO Pharmaceuticals to Participate in Leerink Swann Solid Tumors Roundtable Conference
   Read more >

04/14/2008
   AVEO Pharmaceuticals’ Novel Triple VEGF Receptor Inhibitor Shows Tumor Regression in Patients with Advanced Renal Cancer; Clinical Activity and Tolerability in other Solid Tumors including Colon and Lung Cancers
   Read More >

AVEO is developing a pipeline of targeted therapies which address major unmet medical needs in the field of oncology. The two lead products; AV-951 and AV-412, are in phases II and I, respectively.
Our Products >